EUVIMEDEUVIMED entdecken
Open Access

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK –driven lung cancer by concurrent integrin and MET signaling

Qianqian Hu iD, Lily L Remsing Rix iD, Bina Desai iD, Daria Miroshnychenko iD, Xueli Li iD, Eric A Welsh iD, Bin Fang iD, Gabriela M Wright iD, Neelkamal Chaudhary, Jodi L Kroeger iD, Robert C Doebele iD, John M Koomen iD und 3 weitere

Science Signaling · 2025

DOI: 10.1126/scisignal.ads7662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Signaling, 2025. Verfasst von Qianqian Hu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Cancer-Associated Fibroblasts, Oncogene Proteins, Fusion, Drug Resistance, Neoplasm. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Florida Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-associated fibroblasts (CAFs) are associated with tumor progression and drug resistance. Here, we investigated the mechanisms underlying the cross-talk between CAFs and tumor cells in non–small cell lung cancer (NSCLC). In NSCLC cell lines with EML4-ALK fusions, we observed substantial CAF-mediated drug resistance to clinically used inhibitors of the tyrosine kinase ALK. Array-based cytokine profiling of CAF-derived conditioned medium indicated that a major contributor to the phenomenon was the secreted growth factor HGF, and blocking its receptor MET overcame paracrine resistance to ALK inhibition. However, cell-selective labeling of the proteome in cocultures also revealed an equally important contribution by the fibronectin-integrin pathway, specifically integrin β 1 , which was confirmed through pharmacological inhibition and cell-specific silencing or knockout. Concurrent targeting of MET and integrin signaling effectively abrogated ALK inhibitor resistance in EML4-ALK + NSCLC cells cocultured with CAFs. Moreover, the combination of the ALK inhibitor alectinib with the MET inhibitor capmatinib and/or the integrin inhibitor cilengitide was more effective than single-agent treatment in suppressing tumor growth in allografted mice. The findings illustrate a previously unappreciated complex nature of concurrent paracrine and juxtacrine mechanisms of CAF-driven resistance that may inform the development of more effective therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCancer-Associated FibroblastsOncogene Proteins, FusionDrug Resistance, NeoplasmProto-Oncogene Proteins c-metSignal TransductionCarcinoma, Non-Small-Cell LungProtein Kinase InhibitorsAnaplastic Lymphoma KinaseIntegrin beta1HumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysCoculture Techniques

Substanzen

Oncogene Proteins, FusionProto-Oncogene Proteins c-metEML4-ALK fusion protein, humanProtein Kinase InhibitorsMET protein, humanAnaplastic Lymphoma KinaseIntegrin beta1ALK protein, human

Autor:innen und Institutionen

  • Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL 33620, USA.
  • Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Biostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Flow Cytometry Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

ORCID-Profile: Qianqian Hu, Lily L Remsing Rix, Bina Desai, Daria Miroshnychenko, Xueli Li, Eric A Welsh, Bin Fang, Gabriela M Wright, Jodi L Kroeger, Robert C Doebele, John M Koomen, Eric B Haura, Andriy Marusyk, Uwe Rix

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Florida Department of Health
  • Moffitt Cancer Center
  • NIH/NCI

Zitieren

APA

Hu, Q., Remsing Rix, L. L., Desai, B., Miroshnychenko, D., Li, X., Welsh, E. A., Fang, B., Wright, G. M., Chaudhary, N., Kroeger, J. L., Doebele, R. C., Koomen, J. M., Haura, E. B., Marusyk, A., & Rix, U. (2025). Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK –driven lung cancer by concurrent integrin and MET signaling. Science Signaling. https://doi.org/10.1126/scisignal.ads7662

Vancouver

Hu Q, Remsing Rix LL, Desai B, Miroshnychenko D, Li X, Welsh EA, et al. Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK –driven lung cancer by concurrent integrin and MET signaling. Science Signaling. 2025. doi:10.1126/scisignal.ads7662

BibTeX
@article{Hu2025,
  author = {Hu, Qianqian and Remsing Rix, Lily L and Desai, Bina and Miroshnychenko, Daria and Li, Xueli and Welsh, Eric A and Fang, Bin and Wright, Gabriela M and Chaudhary, Neelkamal and Kroeger, Jodi L and Doebele, Robert C and Koomen, John M and Haura, Eric B and Marusyk, Andriy and Rix, Uwe},
  title = {Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK –driven lung cancer by concurrent integrin and MET signaling},
  journal = {Science Signaling},
  year = {2025},
  doi = {10.1126/scisignal.ads7662}
}
Kostenlos starten →